The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study.
 
JinHu Wang
No Relationships to Disclose
 
Wenbin Li
No Relationships to Disclose
 
Kang Zeng
No Relationships to Disclose
 
Xiaoxi Lin
No Relationships to Disclose
 
Yanling Li
No Relationships to Disclose
 
Zhonghai Guan
No Relationships to Disclose
 
Zhuang Kang
No Relationships to Disclose
 
Changxing Li
No Relationships to Disclose
 
Xiaojie Hu
No Relationships to Disclose
 
Yaohui Ma
No Relationships to Disclose
 
Zhuli Wu
Employment - Fosun Pharma
 
Xingli Wang
Employment - Fosun Pharma
 
Hongmei Lin
Employment - Fosun Pharma
 
Wen Zhong
Employment - Fosun Pharma